1st Meeting of the Society of the Novel Action of Sirolimus (JASMIN Society)

Date and time: Saturday, October 10, 2020, 2:00 pm to 6:00 pm (online)

Opening remarks
Toshinori Takada, Uonuma Institute of Community Medicine, Niigata University Medical & Dental Hospital

General address
Moderator: Nobuyuki Takei, Department of Molecular Neurobiology, Basic Neuroscience Branch, Niigata University Brain Research Institute

Topic 1: "Large-scale signal analysis downstream of mTOR through quantitative phosphoproteomics"
Hirokazu Nakatsumi, Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Nagoya City University

Topic 2: "Basic research and collaboration as two cornerstones for overcoming tuberous sclerosis complex"
Toshiyuki Kobayashi, Dept. of Experimental Pathology, Graduate School of Medicine, Juntendo University

Topic 3: "Proposal for a hemadsorption model-based method to determine optimal sirolimus dosage in LAM patients"
Takahiro Tanaka, Center for Medical Innovation Division of Pioneering Advanced Therapeutics, Niigata University Medical & Dental Hospital

Topic 4: "Clinical studies and clinical trials of sirolimus for focal cortical dysplasia (FCD) type II epilepsy"
Mitsuhiro Kato, Department of Pediatrics, School of Medicine, Showa University

General address
Moderator: Masaru Suzuki, Course of Respiratory Medicine, Department of Internal Medicine, Graduate School of Medicine, Hokkaido University

Topic 5: "Sirolimus therapy for refractory vascular abnormality"
Michio Koseki, Department of Pediatrics, Gifu University

Topic 6: "Potential efficacy of mTOR inhibitors for primary immunodeficiency"
Akifumi Endo, Clinical Research Center, Department of Pediatrics, Medical Hospital, Tokyo Medical & Dental University

Topic 7: "State of sirolimus treatment for lymphangioleiomyomatosis in our Department"
Masaru Suzuki, Course of Respiratory Medicine, Department of Internal Medicine, Graduate School of Medicine, Hokkaido University

Topic 8: "Adverse events observed in the studies of sirolimus therapy for lymphangioleiomyomatosis"
Toshinori Takada, Uonuma Institute of Community Medicine, Niigata University Medical & Dental Hospital

General discussion
Moderator: Toshinori Takada, Uonuma Institute of Community Medicine, Niigata University Medical & Dental Hospital

Closing remarks
Koh Nakata, Center for Medical Innovation Division of Pioneering Advanced Therapeutics, Niigata University Medical & Dental Hospital

Secretariat: Center for Medical Innovation Division of Pioneering Advanced Therapeutics, Niigata University Medical & Dental Hospital
TEL 025-227-2029　E-mail：jasmin@med.niigata-u.ac.jp